Bharat Biotech confirms deal with Brazil to supply 20 million doses of COVAXIN

“The company has signed an agreement to supply COVAXIN®️ during Q2 and Q3 2021. The company is delighted to partner with Brazil in the fight against Covid-19 and to support its immunization program against the virus,” said Bharat Biotech in a statement.

There is strong interest in COVAXIN®️ from many countries around the world, and the company is fully committed to ensuring supplies quickly and efficiently, it continued.

Krishna Ella, chairman and general manager of Bharat Biotech recently said that the vaccine manufacturer in Hyderabad will commission its third facility by the end of this week and be able to produce at least 40 million doses of the vaccine every month thereafter. . He said increased production of the vaccine could potentially help reduce the global deficit.

Bharat Biotech also announced earlier this month that it will sign a pact with Ocugen Inc that will allow the US-based biopharmaceutical company to co-develop, supply and commercialize the Indian vaccine maker’s Covid-19 vaccine Covaxin in the US market. agreement, Ocugen will own the commercial rights to the vaccine candidate in the US and will be responsible for conducting clinical trials and obtaining emergency use approval (EUA) from the US Food and Drug Administration.

Indicating a move towards the Covaxin vaccine as a viable option to combat the pandemic and open new markets, the company has also sought permission from the governments in Bangladesh and Myanmar to conduct clinical trials.

Bharat Biotech in India had been granted an emergency license by the Drugs Controller General of India VG Somani for its fully inactivated SARS-COV2 vaccine, despite having no efficacy data, after which the vaccine administration began on January 16. The company has said it will release the first batch of interim efficacy data for Covaxin from the ongoing Phase 3 studies within two weeks.